1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Pfizer Inc  
Pfizer Pharmaceuticals Group  
235 East 42nd Street  
New York, New York 10017  
1-212-573-2222  

Pfizer Ltd  
Ramsgate Road  
Sandwich, Kent  
CT13 9NJ  
United Kingdom  
+00 44 (0)1304 616161  

Emergency telephone number: CHEMTREC (24 hours): 1-800-424-9300  
Emergency telephone number: ChemSafe (24 hours): +44 (0)208 762 8322  

Material Name: Tramadol Hydrochloride Capsules  
Trade Name: Nobligan; Tramal  
Chemical Family: Mixture  
Intended Use: Pharmaceutical product used as analgesic  

2. COMPOSITION/INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS List</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tramadol Hydrochloride</td>
<td>73806-49-2</td>
<td>Not listed</td>
<td>50 mg***</td>
</tr>
<tr>
<td>Microcrystalline cellulose</td>
<td>9004-34-6</td>
<td>232-674-9</td>
<td>*</td>
</tr>
<tr>
<td>Iron oxide</td>
<td>1309-37-1</td>
<td>215-168-2</td>
<td>*</td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>557-04-0</td>
<td>209-150-3</td>
<td>*</td>
</tr>
<tr>
<td>Colloidal silicon dioxide</td>
<td>7631-86-9</td>
<td>231-545-4</td>
<td>*</td>
</tr>
<tr>
<td>Titanium dioxide</td>
<td>13463-67-7</td>
<td>236-675-5</td>
<td>*</td>
</tr>
<tr>
<td>Sodium lauryl sulfate</td>
<td>151-21-3</td>
<td>205-788-1</td>
<td>*</td>
</tr>
<tr>
<td>Iron Hydroxide</td>
<td>11113-66-9</td>
<td>234-346-0</td>
<td>*</td>
</tr>
<tr>
<td>Gelatin</td>
<td>9000-70-8</td>
<td>232-554-6</td>
<td>*</td>
</tr>
<tr>
<td>Sodium starch glycolate</td>
<td>9063-38-1</td>
<td>Not listed</td>
<td>*</td>
</tr>
<tr>
<td>Indigotin I (E 132)</td>
<td>482-89-3</td>
<td>207-586-9</td>
<td>*</td>
</tr>
</tbody>
</table>

** * Proprietary  
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

Additional Information:  
*** per tablet/capsule/lozenge/suppository  
* Proprietary

3. HAZARDS IDENTIFICATION

Appearance: Capsules  
Signal Word: WARNING  

Statement of Hazard: Harmful if swallowed.  
May cause central nervous system effects  

Additional Hazard Information:  
Short Term: May cause eye irritation; May cause skin irritation. (based on components) May be harmful if swallowed. (based on animal data)  
Long Term: Use of this drug is habit forming. Addiction may occur.
Known Clinical Effects: Ingestion of this material may cause effects similar to those seen in clinical use including dry mouth, drowsiness, headache, dizziness, nausea, vomiting, weakness, anxiety, and dilated pupils. Cases of severe overdose may lead to respiratory depression, hypotension, coma, convulsions, cardiac arrhythmia, and tachycardia.

EU Indication of danger: Harmful

EU Hazard Symbols: 

EU Risk Phrases: R22 - Harmful if swallowed.

Note: This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

4. FIRST AID MEASURES

Eye Contact: Immediately flush eyes with water for at least 15 minutes. If irritation occurs or persists, get medical attention.

Skin Contact: Remove clothing and wash affected skin with soap and water. This material may not be completely removed by conventional laundering. Consult professional laundry service. Do not home launder. If irritation occurs or persists, get medical attention.

Ingestion: Get medical attention. Do not induce vomiting unless directed by medical personnel. Never give anything by mouth to an unconscious person.

Inhalation: Remove to fresh air. If not breathing, give artificial respiration. Get medical attention.

5. FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire.

Fire Fighting Procedures: During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

Fire / Explosion Hazards: Not applicable

6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions: Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

Measures for Environmental Protections: Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.
Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

General Handling: If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing.

Storage Conditions: Store at room temperature in properly labeled containers. Keep away from heat, sparks and flames.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Microcrystalline cellulose
- OSHA - Final PELs - TWAs: = 15 mg/m³ TWA total
- = 5 mg/m³ TWA
- ACGIH Threshold Limit Value (TWA) = 10 mg/m³ TWA
- Australia TWA = 10 mg/m³ TWA

Iron oxide
- OSHA - Final PELs - TWAs: = 10 mg/m³ TWA
- ACGIH Threshold Limit Value (TWA) = 5 mg/m³ TWA
- Australia TWA = 5 mg/m³ TWA

Magnesium stearate
- ACGIH Threshold Limit Value (TWA) = 10 mg/m³ TWA except stearates of toxic metals
- Australia TWA = 10 mg/m³ TWA

Colloidal silicon dioxide
- OSHA - Final PELs - Table Z-3 Mineral D: (80)/(% SiO2) mg/m³ TWA
  = 20 mppcf TWA
- Australia TWA = 2 mg/m³ TWA

Titanium dioxide
- OSHA - Final PELs - TWAs: = 15 mg/m³ TWA total
- ACGIH Threshold Limit Value (TWA) = 10 mg/m³ TWA
- Australia TWA = 10 mg/m³ TWA

Sodium lauryl sulfate
- Pfizer OEL TWA-8 Hr: 0.3 mg/m³
- Pfizer STEL 0.75 mg/m³
- The exposure limit(s) listed for solid components are only relevant if dust may be generated.

Engineering Controls: Engineering controls should be used as the primary means to control exposures.

Personal Protective Equipment:
- Hands: Not required for the normal use of this product. Wear protective gloves when working with large quantities.
- Eyes: Not required under normal conditions of use. Wear safety glasses or goggles if eye contact is possible.
- Skin: Not required for the normal use of this product. Wear protective clothing when working with large quantities.
Respiratory Protection: Respiratory protection is recommended as a precaution to minimize exposure when handling this material in bulk. Not required for the normal use of this product. If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

9. Physical and Chemical Properties:

<table>
<thead>
<tr>
<th>Physical State:</th>
<th>Capsule</th>
<th>Color:</th>
<th>No data available.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular Formula:</td>
<td>Mixture</td>
<td>Molecular Weight:</td>
<td>Mixture</td>
</tr>
</tbody>
</table>

10. Stability and Reactivity

| Stability: | Stable under normal conditions of use. |
| Conditions to Avoid: | None known |
| Incompatible Materials: | As a precautionary measure, keep away from strong oxidizers. |

11. Toxicological Information

| General Information: | There are no data for this formulation. The information included in this section describes the potential hazards of the individual ingredients. |

**Acute Toxicity (Species, Route, End Point, Dose)**

**Tramadol Hydrochloride**
- Rat Oral LD50 228 mg/kg
- Rat Intravenous LD50 57.6 mg/kg
- Rat Subcutaneous LD50 286 mg/kg
- Mouse Oral LD50 270 mg/kg
- Mouse Intravenous LD50 60.4 mg/kg

**Microcrystalline cellulose**
- Rat Oral LD50 > 5000 mg/kg
- Rabbit Dermal LD50 > 2000 mg/kg

**Magnesium stearate**
- Rat Oral LD50 > 2000 mg/kg
- Rat Inhalation LC50 > 2000 mg/m³

**Titanium dioxide**
- Rat Oral LD50 > 7500 mg/kg
- Rat Subcutaneous LD 50 50 mg/kg

**Sodium lauryl sulfate**
- Rat Oral LD50 1288 mg/kg

**Acute Toxicity Comments:** A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

**Irritation / Sensitization (Study Type, Species, Severity)**

**Microcrystalline cellulose**
- Skin Irritation Rabbit Non-irritating
- Eye Irritation Rabbit Non-irritating
12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been thoroughly investigated. Releases to the environment should be avoided.
13. DISPOSAL CONSIDERATIONS

Disposal Procedures: Dispose of waste in accordance with all applicable laws and regulations.

14. TRANSPORT INFORMATION

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

EU Symbol: Xn
EU Indication of danger: Harmful

EU Risk Phrases: R22 - Harmful if swallowed.

EU Safety Phrases: S22 - Do not breathe dust.

OSHA Label: WARNING Harmful if swallowed. May cause central nervous system effects

Canada - WHMIS: Classifications

WHMIS hazard class: Class D, Division 1, Subdivision B

Iron Hydroxide
   Standard for the Uniform Scheduling for Drugs and Poisons: Schedule 2
   Schedule 4
   Schedule 5
   Schedule 6
   EU EINECS List: 234-346-0

Microcrystalline cellulose
   Inventory - United States TSCA - Sect. 8(b): XU
   Australia (AICS): Present
   EU EINECS List: 232-674-9

Iron oxide
   Inventory - United States TSCA - Sect. 8(b): Present
### 16. OTHER INFORMATION

<table>
<thead>
<tr>
<th>Substance</th>
<th>Inventory - United States TSCA - Sect. 8(b)</th>
<th>Australia (AICS):</th>
<th>EU EINECS List</th>
</tr>
</thead>
<tbody>
<tr>
<td>Magnesium stearate</td>
<td>Present</td>
<td>Present</td>
<td>209-150-3</td>
</tr>
<tr>
<td>Colloidal silicon dioxide</td>
<td>Present</td>
<td>Present</td>
<td>231-545-4</td>
</tr>
<tr>
<td>Titanium dioxide</td>
<td>Present</td>
<td>Present</td>
<td>236-675-5</td>
</tr>
<tr>
<td>Sodium starch glycolate</td>
<td>XU</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sodium lauryl sulfate</td>
<td>Present</td>
<td>Present</td>
<td>205-788-1</td>
</tr>
<tr>
<td>Indigotin I (E 132)</td>
<td>Present</td>
<td>Present</td>
<td>207-586-9</td>
</tr>
</tbody>
</table>

**Reasons for Revision:**
Updated Section 2 - Composition / Information on Ingredients. Updated Section 3 - Hazard Identification. Updated Section 5 - Fire Fighting Measures. Updated Section 6 - Accidental Release Measures. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 10 - Stability and Reactivity. Updated Section 11 - Toxicology Information. Updated Section 13 - Disposal Considerations.

**Prepared by:**
Toxicology and Hazard Communication  
Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied.

End of Safety Data Sheet